Akero Therapeutics Inc
General ticker "AKRO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.1B
Akero Therapeutics Inc follows the US Stock Market performance with the rate: 56.0%.
Estimated limits based on current volatility of 3.5%: low 27.86$, high 29.89$
Factors to consider:
- Price in estimated range
- Earnings for 18 months up through Q2 (+1 year) are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2022-12-31 to 2024-12-30
- 2022-12-31 to 2023-12-31 estimated range: [21.44$, 46.64$]
- 2023-12-31 to 2024-12-30 estimated range: [16.03$, 36.27$]
Financial Metrics affecting the AKRO estimates:
- Negative: Non-GAAP EPS, $ of -2.92 <= 0.10
- Negative: Operating profit margin, % of -100 <= 1.03
- Negative: Operating cash flow per share per price, % of -5.07 <= 2.35
- Negative: negative Net income
- Positive: Interest expense per share, $ of 0.02 <= 0.14
- Positive: Inventory ratio change, % of 0 <= 0
Short-term AKRO quotes
Long-term AKRO plot with estimates
Financial data
YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|
Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
Operating Expenses | $100.89MM | $115.16MM | $172.87MM |
Operating Income | $-100.89MM | $-115.16MM | $-172.87MM |
Non-Operating Income | $0.11MM | $3.12MM | $21.11MM |
Interest Expense | $0.00MM | $0.74MM | $3.10MM |
R&D Expense | $81.76MM | $85.28MM | $141.80MM |
Income(Loss) | $-100.78MM | $-112.03MM | $-151.76MM |
Profit(Loss) | $-100.78MM | $-112.03MM | $-151.76MM |
Stockholders Equity | $169.11MM | $326.56MM | $535.31MM |
Assets | $195.55MM | $356.57MM | $580.27MM |
Operating Cash Flow | $-79.68MM | $-92.52MM | $-145.37MM |
Investing Cash Flow | $42.28MM | $-63.83MM | $-223.62MM |
Financing Cash Flow | $0.60MM | $255.63MM | $353.32MM |
Earnings Per Share* | $-2.89 | $-2.79 | $-2.89 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.